Skip to content
thestock.space

Sun Pharmaceutical Industries (SUNPHARMA) had a P/E of 40.7× on 6 Nov 2026, above the industry P/E of 28.7×. Sales and net profit grew 10% and 11% a year over 3 years, with ROCE of 18% and ROE of 13%. It carries very little debt, and its dividend yield is 0.9%. It is a large-cap company with a market cap of ₹4.5 lakh crore, the largest of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares rose 8.2% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Sep 2026.How we calculate this

past year
Open
₹1,823.00
Day high
₹1,868.90
Day low
₹1,814.70
Prev. close
₹1,829.00
Volume
23.5 L

Health check

2 fair · 4 to check
  • ReturnsBehind

    +8.2% over a year, better than 2 of 7 peers.

  • Price tagPricier

    P/E 40.7 vs industry 28.7.

  • GrowthSlow

    Sales +10.4%, profit +10.6% a year over 3 years.

  • ProfitabilityAverage

    ROCE 17.9% vs peer median 14.9%.

  • Balance sheetFair

    Practically debt-free, Piotroski 5 of 9.

  • Red flags1 to check

    Quarterly profit down 36.2% on a year ago.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Large cap

₹4.5L Cr, the largest of 154 in its industry.

Market sensitivity

Measuring against the NIFTY 50…

Key metrics

Last 12 months to Sep 2026: sales ₹61,631 Cr · profit ₹10,966 Cr
Market cap
₹4.5L Cr
Large cap
P/E
40.7
Industry 28.7
Price to book
4.99
Peers 5.97
Dividend yield
0.86%
ROE
13.1%
Peers 14.7%
ROCE
17.9%
Peers 14.9%
Debt to equity
0.04
Debt ₹3,241 Cr
EPS (TTM)
₹45.70
Face value ₹1
OPM (TTM)
28.2%
Net margin 17.8%
Sales growth
+11.9%
Latest quarter vs a year ago
Profit growth
−36.2%
Latest quarter vs a year ago
Price to sales
7.24
EV/EBITDA 24.3

Strengths and risks

Strengths

  • Practically debt-free.
  • Positive operating cash flow in each of the last 4 years.

Risks to check

  • Quarterly profit down 36.2% on a year ago.

Derived automatically from reported figures. Not a recommendation.

About Sun Pharmaceutical Industries

Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations, and active pharmaceutical ingredients (APIs) in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including neuropsychiatry, cardiology, diabetes, gastroenterology, pain/analgesics, gynecology, ophthalmology, urology, dermatology, respiratory,…

Headquarters
Mumbai
Employees
47,000
Sector
Healthcare
ISIN
INE044A01036
Website
sunpharma.com

Price range

52 weeks

₹1,583.70₹2,046.90

Today

₹1,814.70₹1,868.90
Avg volume (3M)
17.5 L
1-year return
plus 8.2%
From 52-week high
minus 9.1%

Analyst consensus

33 analysts
BuyMean target ₹2,111.94 plus 13.5%

Target range, with today’s price

Low ₹1,770.00High ₹2,320.00

Next results expected around 28 Jan 2027

Consensus from Yahoo Finance. Not a recommendation.

Peers · Drug Manufacturers - Specialty & Generic

Compare with peersScreen the whole industry
Company
SUNPHARMASun Pharmaceutical Industries1,860.00plus 1.69%4,46,27640.74.9917.9%13.1%28.2%10.4%10.6%0.86%plus 8.2%
DIVISLABDivi's Laboratories10,320.50plus 1.78%2,73,97793.616.3519.0%16.2%34.9%11.0%12.1%0.29%plus 49.0%
TORNTPHARMTorrent Pharmaceuticals4,750.00plus 0.85%1,80,67580.29.839.1%15.7%33.7%13.3%20.2%0.80%plus 31.7%
LAURUSLABSLaurus Labs2,340.00minus 0.26%1,26,43394.420.8619.5%24.0%30.4%3.8%4.0%0.09%plus 138.6%
ZYDUSLIFEZydus Lifesciences1,197.90plus 0.41%1,19,49128.64.2919.0%14.7%26.2%16.5%37.0%0.08%plus 22.8%
DRREDDYDr. Reddy's Laboratories1,373.00plus 0.51%1,14,46240.92.9614.2%7.3%15.9%11.0%−1.7%0.58%plus 13.8%
CIPLACipla1,411.00plus 0.49%1,13,99339.43.2214.9%8.3%17.3%7.2%11.5%0.92%minus 6.6%
MANKINDMankind Pharma2,540.00plus 0.87%1,04,91346.85.9713.7%13.6%26.5%17.7%14.3%0.00%plus 6.3%
Median of 7 peers–0.51%1,19,49146.85.9714.9%14.7%26.5%11.0%12.1%0.29%22.8%

Quarterly results

Consolidated, ₹ crore
SalesSelect a row below to chart it
₹ CrJun 25Dec 25Mar 26Jun 26Sep 26
13,78615,46914,56015,18416,100
9,71310,67511,03210,88811,435
4,0734,7953,5274,2964,665
29.5%31.0%24.2%28.3%29.0%
694733885846596
74.878.485.999.774.7
701732775739758
−818−489–−204−1,269
3,1734,2273,5514,0993,159
27.4%19.5%23.3%29.0%36.6%
2,2793,3692,7142,8951,989
9.5014.0011.3012.108.30

Sep 25 not reported by the data source.

Profit & loss

Yearly, ₹ crore
Sales CAGR 3Y
+10.4%
Profit CAGR 3Y
+10.6%
EPS CAGR 3Y
+10.6%
ROE
13.1%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
43,27947,75852,04158,220
–+10.4%+9.0%+11.9%
31,47134,73436,88541,687
11,80813,02515,15716,533
27.3%27.3%29.1%28.4%
4851,2691,5692,316
172238231339
2,5302,5572,5752,938
−181−411−167−453
9,40811,08813,75215,119
9.0%13.0%20.2%23.5%
8,4749,57610,92911,479
–+13.0%+14.1%+5.0%
35.3039.9045.6047.80

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
240240240240
55,75563,42771,97883,330
6,8863,2742,3624,627
17,86218,55917,52020,588
80,74485,50092,1011,08,785
11,48411,48911,48712,637
1,0941,2971,4511,523
5,1526,0654,3743,141
15,41519,32926,31833,781
47,59947,32148,47257,703
80,74485,50092,1011,08,785

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
4,95912,13514,07212,419
−7,944−690−5,306−11,344
2,376−6,710−7,906−2,513
−6084,735860−1,437
−2,086−2,202−2,129−3,609
2,8749,93311,9448,810
−2,519−2,898−3,614−3,934

Shareholding pattern

Source: NSE filings
52.7%
promoters
  • Promoters52.68%
  • Public47.32%
  • As of 30 Sep 2026
QuarterSplitPromotersPublicPromoter change
30 Sep 202652.68%47.32%minus 1.80
30 Jun 202654.48%45.52%0.00
31 Mar 202654.48%45.52%0.00
31 Dec 202554.48%45.52%0.00
30 Sep 202554.48%45.52%–

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you